Skip to Content

The first-in-class antibody talquetamab show a high clinical response rate in patients with relapsed and refractory multiple myeloma

Talquetamab is a first-in-class bispecific immunoglobulin G4 antibody that binds to CD3 and GPRC5D for activating T cells to attack multiple myeloma cells. The phase I study MonumentTAL-1 has shown high clinical response rate in patients with relapsed and refractory multiple myeloma.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top